MAGIC-G1 Study Provides Updated Findings With MTX110 in Recurrent Glioblastoma
An update on PFS and OS data from the phase 1 MAGIC-G1 study of MTX110 in recurrent glioblastoma has been released.
Related Articles
Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma
Isa-RVd given as induction treatment without consolidation led to a 30% reduction in the risk of disease progression or death vs RVd in multiple myeloma.
Selpercatinib Treatment Beyond Progression in RET Fusion–Positive Non–Small Cell Lung Cancer | JCO Oncology Advances
PURPOSESelpercatinib, a highly selective RET kinase inhibitor with CNS activity, is approved in multiple countries for patients with RET fusion–positive non–small cell lung cancer (NSCLC).METHODSPatients…
Cardiac Events and Survival in EGFR-Mutant NSCLC Treated With Osimertinib
This cohort study examines whether osimertinib is associated with a higher incidence of cardiac toxic effects compared with earlier-generation epidermal growth factor receptor tyrosine kinase…
Improved risk stratification of SMM using trajectory data in the PANGEA 2.0 model
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the new PANGEA 2.0 model, which aims to improve risk stratification of smoldering multiple myeloma (SMM)…
Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis
Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.
Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL
Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over SOC chemoimmunotherapy in patients with treatment-naive CLL.
Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study | JCO Global Oncology
PURPOSETrimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy (MRM),…
Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL
Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.
Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma
Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
Optimizing Treatment Sequences Remains Key in CLL/SLL
Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.